Antibiotic Treatment in Ventilator Associated Tracheobronchitis (VAT)
Information source: Assaf-Harofeh Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Tracheobronchitis
Intervention: Piperacillin/Tazobactam for 7 days (Drug)
Phase: Phase 2/Phase 3
Status: Recruiting
Sponsored by: Assaf-Harofeh Medical Center Official(s) and/or principal investigator(s): Arie Soroksky, MD, Principal Investigator, Affiliation: Tel Aviv University, Faculty of Medicine, Israel.
Overall contact: Arie Soroksky, MD, Phone: 972-8-9779320, Email: soroksky@gmail.com
Summary
Mechanically Ventilated patients in the intensive care unit (ICU) often present with fever,
and purulent sputum, but without radiological evidence of pneumonia.
These patients may have tracheobronchitis. Some suspect that this condition precedes the
development of pneumonia. Antibiotic treatment in tracheobronchitis is controversial.
The investigators will recruit patients with tracheobronchitis and randomize them into 2
groups. One group will be treated with antibiotics and the other group will serve as
control.
Clinical Details
Official title: Antibiotic Treatment in Ventilator Associated Tracheobronchitis (VAT): A Randomized, Controlled Trial
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Rate of development of new pneumonia
Secondary outcome: ICU length of stay (LOS) and mortality
Detailed description:
Patients with proved tracheobronchitis who are mechanically ventilated for more than 48 hrs,
will undergo a CT scan to rool our pneumonia that may not be seen on a routine chest x-ray.
After ruling out pneumonia by CT scan, patients will be randomized into 2 groups.
Intervention group will receive 7 days of treatment with Piperacillin/Tazobactam. A control
group will receive nothing.
Primary endpoint wil be the rate of new pneumonias and secondary endpoint will be ICU Length
of stay, days on mechanical ventilation and 28 day mortality.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Tracheobronchitis as defined by:
- Purulent sputum with > 10 x 4 CFU
- Leukocytosis or leukopenia
- Fever
- No pneumonia on CT scan
Exclusion Criteria:
- Recent treatment of pneumonia
- Abnormal Chest X-ray
- Evidence of Pneumonia on CT scan
Locations and Contacts
Arie Soroksky, MD, Phone: 972-8-9779320, Email: soroksky@gmail.com
Assaf Harofe MC, Beer Yakov, Zerifin 70300, Israel; Recruiting Arie Soroksky, M.D., Phone: 972-8-9779320, Email: soroksky@gmail.com Arie Soroksky, M.D., Principal Investigator
Additional Information
Starting date: September 2009
Last updated: December 8, 2009
|